[go: up one dir, main page]

BR9611047A - Processo de deteção de ciclo oxigenase-2 - Google Patents

Processo de deteção de ciclo oxigenase-2

Info

Publication number
BR9611047A
BR9611047A BR9611047-3A BR9611047A BR9611047A BR 9611047 A BR9611047 A BR 9611047A BR 9611047 A BR9611047 A BR 9611047A BR 9611047 A BR9611047 A BR 9611047A
Authority
BR
Brazil
Prior art keywords
oxygenase
cycle
detection process
mammal
detected
Prior art date
Application number
BR9611047-3A
Other languages
English (en)
Inventor
Peter C Isakson
Karen Seibert
John J Talley
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of BR9611047A publication Critical patent/BR9611047A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção:<B>"PROCESSO DE DETEçãO DE CICLO OXIGENASE-2"<D>. A invenção refere-se a um processo de deteção de concentrações de ciclo oxigenase-2 em um mamífero, o processo compreendendo: administração ao mamífero de uma quantidade diagnosticamente efetiva de um agente seletivo de ciclo oxigenase-2, que seja capaz de ser detectado in vivo; e b) deteção do agente e assim a concentração de ciclo oxigenase-2 é detectada.
BR9611047-3A 1995-10-17 1996-10-16 Processo de deteção de ciclo oxigenase-2 BR9611047A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US568695P 1995-10-17 1995-10-17
PCT/US1996/016440 WO1997014679A2 (en) 1995-10-17 1996-10-16 Method of detecting cyclooxygenase-2

Publications (1)

Publication Number Publication Date
BR9611047A true BR9611047A (pt) 2000-03-08

Family

ID=21717184

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611047-3A BR9611047A (pt) 1995-10-17 1996-10-16 Processo de deteção de ciclo oxigenase-2

Country Status (10)

Country Link
US (2) US6045773A (pt)
EP (1) EP0859642A2 (pt)
JP (1) JP2000510816A (pt)
KR (1) KR19990064310A (pt)
AU (1) AU716582B2 (pt)
BR (1) BR9611047A (pt)
CA (1) CA2234633A1 (pt)
NO (1) NO981708L (pt)
NZ (1) NZ322674A (pt)
WO (1) WO1997014679A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
CA2422803A1 (en) * 2000-08-07 2002-02-14 Vanderbilt University Detection of cox-2 activity and anandamide metabolites
IL159320A0 (en) * 2001-06-12 2004-06-01 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
MXPA04003451A (es) 2001-10-09 2005-02-17 Dimensional Pharm Inc Difeniloxazoles substituidos, la sintesis de los mismos y el uso de los mismo como detectores fluorescencia.
US7154007B2 (en) 2001-10-10 2006-12-26 Hitachi High-Technologies Corporation Luminous compounds and labeling reagents using the same
US7329401B2 (en) 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
US7314709B2 (en) * 2002-08-06 2008-01-01 Vanderbilt University Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism
AU2003270752A1 (en) * 2002-09-27 2004-04-19 King Pharmaceuticals Research And Development, Inc. A method to demonstrate the efficacy of pharmacological stress agent
TW200505446A (en) * 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
WO2005002293A2 (en) * 2003-06-25 2005-01-06 Vanderbilt University Cox-2-targeted imaging agents
US7112601B2 (en) * 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
AU2005227745C1 (en) * 2004-04-01 2009-02-26 Zoetis Services Llc Crystalline pyrazole derivative
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
EP1744747A4 (en) * 2004-04-26 2009-12-02 Univ Vanderbilt INDIC ACID AND INDULECTIC ACID DERIVATIVES AS THERAPEUTIC ACTIVITIES WITH REDUCED GASTROINTESTINAL TOXICITY
US20080138282A1 (en) * 2004-06-03 2008-06-12 The Trustees Of Columbia University In The City Of New York Radiolabeled Arylsulfonyl Compounds and Uses Thereof
CN101098960A (zh) * 2005-01-04 2008-01-02 诺瓦提斯公司 人fpps的x射线结构以及用于选择fpps结合化合物的用途
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
US8303935B2 (en) * 2006-05-19 2012-11-06 Nihon Medi-Physics Co., Ltd. Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid
CA2657691A1 (en) * 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
KR20090025282A (ko) * 2006-06-21 2009-03-10 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
JPWO2008056481A1 (ja) * 2006-11-09 2010-02-25 日本メジフィジックス株式会社 放射性画像診断剤
CA2669522A1 (en) * 2006-11-17 2008-05-22 Nihon Medi-Physics Co., Ltd. Novel compounds with affinity for amyloid
CA2670436A1 (en) * 2006-11-30 2008-06-05 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
WO2008075522A1 (ja) * 2006-12-21 2008-06-26 Nihon Medi-Physics Co., Ltd. 放射性画像診断剤
WO2008091530A2 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
ES2421886T3 (es) 2007-02-13 2013-09-06 Nihon Mediphysics Co Ltd Método para producción de un agente de representación de imágenes de diagnóstico por radiación
US8247423B2 (en) 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
CN101903381A (zh) * 2007-10-24 2010-12-01 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物
AU2008319985A1 (en) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
TW200922628A (en) * 2007-10-30 2009-06-01 Nihon Mediphysics Co Ltd Use of novel compound having affinity for amyloid, and process for production of the same
FR2926079B1 (fr) 2008-01-03 2012-12-28 Commissariat Energie Atomique Procede de preparation d'un derive de purine marque, ledit derive et ses utilisations
PL2247558T5 (pl) 2008-02-14 2024-10-14 Eli Lilly And Company Nowe środki obrazujące do wykrywania czynnościowych zaburzeń neurologicznych
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US8420052B2 (en) 2008-07-24 2013-04-16 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying AD pathology
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CA2756137C (en) 2009-03-23 2015-11-24 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
EP3160514B1 (en) 2014-06-27 2024-07-31 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
US10053478B2 (en) 2015-01-09 2018-08-21 Reiley Pharmaceuticals, Inc. COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
US12332244B2 (en) 2018-06-08 2025-06-17 Kyungpook National University Industry-Academic Cooperation Foundation Composition for diagnosing diseases associated with COX2 overexpression and screening method therefor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045303A (en) * 1985-05-17 1991-09-03 Neorx Corporation Radiohalogenated small molecules for protein labeling
IL84944A (en) * 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0759432A1 (en) * 1993-01-15 1997-02-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a skin-related condition
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994026731A1 (en) * 1993-05-13 1994-11-24 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1995005395A1 (en) * 1993-08-17 1995-02-23 Fujisawa Pharmaceutical Co., Ltd. Method of diagnosing alzheimer's disease
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
CZ294630B6 (cs) * 1993-11-30 2005-02-16 G. D. Searle & Co. Substituované pyrazolylbenzensulfonamidy pro léčení zánětů
US5459239A (en) * 1994-01-24 1995-10-17 Merck Frosst Canada Inc. Peptide sequences and antipeptide antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2 proteins
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
NZ322674A (en) 1999-08-30
US6045773A (en) 2000-04-04
WO1997014679A2 (en) 1997-04-24
AU716582B2 (en) 2000-03-02
NO981708D0 (no) 1998-04-16
WO1997014679A3 (en) 1997-08-14
KR19990064310A (ko) 1999-07-26
EP0859642A2 (en) 1998-08-26
NO981708L (no) 1998-06-10
JP2000510816A (ja) 2000-08-22
US20010055565A1 (en) 2001-12-27
CA2234633A1 (en) 1997-04-24
AU7662996A (en) 1997-05-07

Similar Documents

Publication Publication Date Title
BR9611047A (pt) Processo de deteção de ciclo oxigenase-2
TR199801343T1 (xx) Helicobacter pylor�&#39; n�n tespiti ile ilgili metod ve donan�m.
BR0210579A (pt) Anticorpos, cadeias pesadas e leves, composição farmacêutica e métodos de detecção do nìvel de opgl em amostra biológia e de tratamento
DE69605184D1 (de) Verabreichung einer substanz in den mund
BR9906287A (pt) Bactéria pertencente ao gênero escherichia e que tem uma capacidade para produzir um l-aminoácido, e, processo para produzir um l-aminoácido
ES2155513T3 (es) Ensayo de escrutinio para la deteccion precoz de neoplasia colorrectal.
BR9809550A (pt) Artigo para higiene dental e processos para manufaturar um artigo para higiene dental, para friccionar uma região interdental de um mamìfero e para gerar um agente ativo na boca.
KR890011606A (ko) 항응고제
BR9609677A (pt) Analisadores de função pulmonar pessoal.
BR9911884A (pt) Preparação farmacêutica
BG102556A (en) Orally applied pharmaceutical composition with modified release containing 5-asa, and a method for the treatment of intestinal diseases
BR9811319A (pt) Método para proteger um animal contra umadoença crÈnica
BR9400807A (pt) Método para medir diretamente a concentração de um ou mais componentes de composições de tratamento de água, métodos para determinar os ciclos de concentração, os requisitos de dosagem de polímero e a perda de polímero em um sistema gerador de vapor d&#39;agua
FR2627084B1 (fr) Formes galeniques solides contenant une ou plusieurs substances peroxydiques liberant de l&#39;oxygene actif et utilisees en hygiene bucco-dentaire ou comme decontaminants de lentilles ophtalmiques
BR9300651A (pt) Processo para determinar a presenca e/ou concentracao de um polimero para tratamento de agua em uma amostra aquosa,hibridoma e composicao
RU94020406A (ru) Способ выявления поражений эпителия желудка и применение дисахаридов для этой цели
EP1115842A4 (en) Fructosamine oxidase assay: methods and materials
KR920014474A (ko) 담석 붕괴용 제제
DE59003060D1 (de) Protein-S-hältige pharmazeutische Präparation.
ES2175120T3 (es) Procedimiento para obtener aminoacidos a partir de proteinas y utilizacion de los productos que contienen aminoacidos.
Ghael et al. The nitric oxide donor S‐nitroso‐N‐acetyl‐D, L‐penicillamine degrades heparan sulfate and heparin
EP1257563A4 (en) THERAPEUTIC AND DIAGNOSTIC METHODS FOR COLITIS ULCEROSA AND RELATED DISEASES
BR9507228A (pt) Processo para detectar a presença de um analito em uma amostra de um fluido corpóreo soluçao tampao para o tratamento de uma amostra de fluido corpóreo a ser ensaiada e kit
RU95108454A (ru) Способ диагностики антифосфолипидного синдрома
Stacey et al. Toxicity of cadmium/chloroform combination in vivo.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.PORTANTO, INDEFIRO O PRESENTE PEDIDO.